The Medical Letter on Drugs and Therapeutics
Idarucizumab (Praxbind) - An Antidote for Dabigatran
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa).1 Idarucizumab is the first specific reversal agent to become available for one of the new oral anticoagulants.2

RISK OF BLEEDING WITH DABIGATRAN — As with all anticoagulants, severe, potentially fatal bleeding can occur with dabigatran. Unlike warfarin, routine laboratory monitoring to determine the extent of anticoagulation is not required with dabigatran and no specific agent has been available to reverse its anticoagulant effect in the event of life-threatening bleeding or emergency surgery. Dabigatran is dialyzable, but dialysis may not be feasible in patients with acute bleeding.3

MECHANISM ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Idarucizumab (Praxbind) - An Antidote for Dabigatran
Article code: 1482a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian